Glucotrack Stock Price, News & Analysis

Glucotrack (Nasdaq: GCTK), a medical technology company focused on diabetes technologies, has announced the pricing of a 'best efforts' public offering of approximately 2.6 million shares of common stock at $1.15 per share. The offering is expected to generate gross proceeds of approximately $3.0 million before deducting placement fees and expenses.

The closing is anticipated to occur around February 5, 2025, subject to customary closing conditions. Dawson James Securities is serving as the sole placement agent for this offering, which is being conducted pursuant to an effective S-3 registration statement previously declared effective by the SEC on October 3, 2024.

Glucotrack (NASDAQ: GCTK) has successfully completed its first human clinical study of a Continuous Blood Glucose Monitor (CBGM). The study, conducted over four days in a hospital setting with six diabetes patients, met its primary endpoint with no procedure or device-related serious adverse events reported.

The CBGM sensor lead was placed in the subclavian vein through a percutaneous procedure, representing the first real-time continuous blood glucose monitor placed in this location. This approach offers direct blood glucose measurement, potentially overcoming limitations of traditional monitors that measure glucose in interstitial fluid.

The device is designed for three years of continuous monitoring with no external body components. While the study focused on safety and procedural aspects rather than sensor accuracy, the system performed similarly to previous animal studies. The successful placement and removal procedures were performed by interventional cardiologists, with monitoring continuing through seven days post-removal.

Glucotrack (NASDAQ: GCTK) has announced a 1-for-20 reverse stock split effective February 4, 2025. The company's outstanding common stock will be reduced from 155,491,473 to approximately 7,774,574 shares, with stockholders' ownership percentages remaining unchanged except for fractional shares, which will be rounded up to the next whole share.

The reverse split, approved by stockholders on January 3, 2025, and ratified by the Board on January 28, 2025, aims to bring Glucotrack into compliance with Nasdaq's $1.00 minimum bid price requirement and attract institutional investors. The company's stock will continue trading on Nasdaq under the symbol 'GCTK' with a new CUSIP number 45824Q705.

VStock Transfer, will serve as the exchange agent, managing the automatic share adjustment process and sending transaction statements to stockholders. Those holding shares through brokers will have their positions automatically adjusted according to their broker's processes.

Glucotrack (Nasdaq: GCTK) has appointed Peter C. Wulff as Chief Financial Officer, effective immediately. Wulff brings over 35 years of financial management experience in the emerging growth life sciences sector, with expertise in both public and private companies.

Wulff's track record includes successful capital raising through public and private equity offerings, debt financing, and strategic business transactions. He previously served as CFO at Biological Dynamics, Inc. and JenaValve Technology, Inc., where he managed the company's corporate relocation from Germany and various capital raise transactions. His experience also includes financial leadership roles at Alphatec Spine Holdings, Artes Medical, CryoCor, and Pure Biosciences.

The appointment aims to support Glucotrack's commercialization of its continuous blood glucose monitor for people with diabetes, with focus on driving financial excellence and advancing the company's strategic vision.

Glucotrack (Nasdaq: GCTK) has achieved ISO 13485:2016 certification from the British Standards Institute (BSI), marking a significant milestone in its development of continuous blood glucose monitoring technology. The certification validates the company's quality management system for medical device design and development.

The achievement follows successful completion of Stage I and Stage II Assessments by BSI, confirming Glucotrack's compliance with ISO 13485:2016 standards. This internationally recognized certification is particularly significant given the FDA's 2024 Quality Management System Regulation Final Rule, which aligns U.S. requirements with global standards through ISO 13485 adoption.

CEO Paul V. Goode emphasized this certification's importance in their journey toward delivering high-quality Continuous Blood Glucose Monitor (CBGM) products for people with diabetes, highlighting the company's commitment to quality and regulatory excellence.

Glucotrack (Nasdaq: GCTK) has appointed Ted Williams as Vice President of Regulatory Affairs, effective immediately. Williams brings nearly 25 years of experience in regulatory affairs and quality assurance for Class III medical devices, including expertise in continuous glucose monitors (CGM) and drug/device combination products.

Williams previously served as Vice President of Regulatory Affairs/Quality Assurance at Glysens Inc, focusing on implantable CGM development. His experience spans roles at Therapeutics Inc. and Cardium Therapeutics, working with various medical technologies.

The appointment aims to advance Glucotrack's human clinical trials and regulatory program for their Continuous Blood Glucose Monitor (CBGM). According to CEO Paul V. Goode, Williams' expertise will be important in navigating FDA pathways as they develop their CBGM technology for diabetes patients.

Glucotrack (Nasdaq: GCTK), a medical technology company specializing in diabetes care technologies, has announced its participation in the upcoming TechBio Showcase™ 2025. The company's President and CEO, Paul V. Goode, will deliver a corporate update focusing on their Continuous Blood Glucose Monitor (CBGM) technology.

The presentation is scheduled for Tuesday, January 14, at 9:30am PT in the Yosemite C track. TechBio Showcase, part of Biotech Showcase™ 2025, is organized by Demy-Colton and EBD Group. This investor conference serves as a networking platform for executives and investors, promoting geographical investment and partnership opportunities in therapeutic development.

Glucotrack (NASDAQ: GCTK) has initiated patient enrollment for a short-term human clinical study of its continuous blood glucose monitor (CBGM). The study includes both type 1 and type 2 diabetes patients, with results expected in 6-8 weeks. The CBGM is a long-term implantable device that measures glucose directly from blood, designed to work for three years without external components. The four-day in-hospital study is being conducted at Instituto do Coração under Dr. Alexandre Abizaid, involving intravascular sensor placement and fixed meal challenges.

Glucotrack (Nasdaq: GCTK) has completed a $10.0 million public offering and concurrent private placement. The offering included 2,437,340 shares of common stock and 4,756,900 pre-funded warrants at $1.39 per share. Each share and warrant came with series A and B common warrants exercisable at $1.81 per share. Additionally, the company converted $4.0 million in outstanding secured convertible notes from July 2024 into equity on similar terms. Dawson James Securities acted as the sole placement agent for the public offering.